Microbial Influences on Amyotrophic Lateral Sclerosis: The Gut–Brain Axis and Therapeutic Potential of Microbiota Modulation

Sclerosis, Journal Year: 2025, Volume and Issue: 3(1), P. 8 - 8

Published: March 5, 2025

Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive degeneration of motor neurons. The gut microbiota, community microorganisms in digestive tract, has recently been implicated ALS pathogenesis through its influence on neuroinflammation and metabolic pathways. This review explores potential role microbiota metabolites progression investigates therapeutic approaches targeting microbiota. Methods: A comprehensive current literature was conducted to assess relationship between composition, microbial metabolites, patients. We searched for published reports ALS, emphasizing complex interplay dysbiosis, neuroinflammation, systemic metabolism. Special emphasis placed studies exploring short-chain fatty acids (SCFAs), bacterial amyloids (curli-like factors), neurotoxins such as β-methylamino-L-alanine (BMAA). liver–gut axis evaluated well. changes would sustain rationale strategies probiotics, prebiotics, fecal transplantation (FMT), dietary interventions. Results: patients exhibit reduced SCFA-producing bacteria an increase potentially pathogenic genera. Of note, different do not agree common patterns being linked supporting need further, more extensive studies. Dysbiosis sometimes correlates with inflammation disrupted liver function, amplifying neuroinflammatory responses. Key including SCFAs, amyloids, BMAA, may exacerbate neuron promoting protein misfolding, oxidative stress, neuroinflammation. Emerging strategies, probiotics FMT, show restoring balance, although clinical data remain limited. Conclusions: could modulate metabolism ALS. Microbiota-targeted therapies, interventions, represent promising avenues mitigating disease progression. Further research required validate these interventions large-scale, longitudinal develop personalized microbiota-based treatments tailored individual phenotypes.

Language: Английский

Gut microbiota immune cross-talk in amyotrophic lateral sclerosis

Neurotherapeutics, Journal Year: 2024, Volume and Issue: 21(6), P. e00469 - e00469

Published: Oct. 1, 2024

Language: Английский